Plasma TGF-β1, TIMP-1, MMP-1 and IL-18 as a combined biomarker of psoriasis activity

Biomarkers

Volumn 13, Issue 5, 2008, Pages 549-556

  Flisiak, Iwona ^a   Zaniewski, Przemysław ^a   Chodynicka, Bozena ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

IL 18; MMP 1; PASI; Psoriasis; TGF 1; TMIP 1

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 18; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MALE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; SCORING SYSTEM; BLOOD; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; INTERLEUKIN-18; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; PSORIASIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA1;

EID: 47949114748     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500802033300     Document Type: Article

References (29)

1. Arican, O., Aral, M., Sasmaz, S. and Ciragil, P. (2005) Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators of Inflammation, 24, pp. 273-279.
2. Baran, W., Szepietowski, JC, Mazur, G. and Baran, E. (2007) TGF-beta(1) gene polymorphism in psoriasis vulgaris. Cytokine, 38, pp. 8-11.
3. Cai, JP, Falanga, V., Taylor, JR and Chin, YH. (1996) Transforming growth factor-beta receptor binding and function are decreased in psoriatic dermal endothelium. Journal of Investigative Dermatology, 106, pp. 225-231.
4. Choi, CP, Kim, YI, Lee, JW and Lee, MH. (2007) The effect of narrowband ultraviolet B on the expression of matrix metalloproteinase-1, transforming growth factor-beta1 and type I collagen in human skin fibroblasts. Clinical & Experimental Dermatology, 32, pp. 180-185.
5. Companjen, AR, Van der Velden, VH, Vooys, A., Debets, R., Benner, R. and Prens, EP. (2000) Human keratinocytes are major producers of IL-18: predominant expression of the unprocessed form. European Cytokine Network, 11, pp. 383-390.
6. Companjen, A., Van der Wel, L., Van der Fits, L., Laman, J. and Prens, E. (2004) Elevated interleukin-18 protein expression in early active and progressive plaque-type psoriatic lesions. European Cytokine Network, 15, pp. 210-216.
7. Flisiak, I., Chodynicka, B., Porebski, P. and Flisiak, R. (2002) Association between psoriasis severity and transforming growth factor beta1 and beta2 in plasma and scales from psoriatic lesions. Cytokine, 19, pp. 121-125.
8. Flisiak, I., Porebski, P., Flisiak, R. and Chodynicka, B. (2003) Plasma-transforming growth factor beta1 as a biomarker of psoriasis activity and treatment efficiency. Biomarkers, 8, pp. 437-443.
9. Flisiak, I., Mysliwiec, H. and Chodynicka, B. (2005) Effect of psoriasis treatment on plasma concentrations of metalloproteinase-1 and tissue inhibitor of metalloproteinases-1. Journal of European Academy of Dermatology & Venereology, 19, pp. 418-421.
10. Flisiak, I., Porebski, P. and Chodynicka, B. (2006) Effect of psoriasis activity on metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in plasma and lesional scales. Acta Dermato-venereologica, 86, pp. 17-21.
11. Flisiak, I., Klepacki, A. and Chodynicka, B. (2006) Plasma and scale levels of interleukin 18 in comparison with other possible clinical and laboratory biomarkers of psoriasis activity. Biomarkers, 11, pp. 194-200.
12. Fredriksson, T. and Pettersson, U. (1978) Severe psoriasis-oral therapy with a new retinoid. Dermatologica, 157, pp. 238-244.
13. Furue, M., Kato, M., Nakamura, K., Nashiro, K., Kikuchi, K., Okochi, H., Miyazono, K. and Tamaki, K. (1997) Dysregulated expression of transforming growth factor beta and its type-I and type-II receptors in basal-cell carcinoma. International Journal of Cancer, 71, pp. 505-509.
14. Gillespie, MT and Horwood, NJ. (1998) Interleukin-18: Perspectives on the newest interleukin. Cytokine and Growth Factors Review, 9, pp. 109-116.
15. Kanda, N., Shimizu, T., Tada, Y. and Watanabe, S. (2007) IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes. European Journal of Immunology, 37, pp. 338-350.
16. Kane, CJ, Knapp, AM, Mansbridge, JN and Hanawalt, PC. (1990) Transforming growth factor-beta 1 localization in normal and psoriatic epidermal keratinocytes in situ. Journal of Cell Physiology, 144, pp. 144-150.
17. Krueger, JG. (2002) The immunologic basis for the treatment of psoriasis with new biologic agents. Journal of the American Academy of Dermatology, 46, pp. 1-23.
18. Leivo, T., Leivo, I., Kariniemi, AL, Keski-Oja, J. and Virtanen, I. (1998) Down-regulation of transforming growth factor-beta receptors I and II is seen in lesional but not non-lesional psoriatic epidermis. British Journal of Dermatology, 138, pp. 57-62.
19. Mee, JB, Alam, Y. and Groves, RW. (2000) Human keratinocytes constitutively produce but do not process interleukin-18. British Journal of Dermatology, 143, pp. 330-336.
20. Myers, A., Lakey, R., Cawston, TE, Kay, LJ and Walker, DJ. (2004) Serum MMP-1 and TIMP-1 levels are increased in patients with psoriatic arthritis and their siblings. Rheumatology, 43, pp. 272-276.
21. Naik, SM, Cannon, G., Burbach, GJ, Singh, SR, Swerlick, RA, Wilcox, JN, Ansel, JC and Caughman, SW. (1999) Human keratinocytes constitutively express interleukin-18 and secrete biologically active interleukin-18 after treatment with pro-inflammatory mediators and dinitrochlorobenzene. Journal of Investigative Dermatology, 113, pp. 766-772.
22. Ohta, Y., Hamada, Y. and Katsuoka, K. (2001) Expression of IL-18 in psoriasis. Archives of Dermatological Research, 293, pp. 334-342.
23. Oyama, N., Iwatsuki, K., Satoh, M., Akiba, H. and Kaneko, F. (2000) Dermal fibroblasts are one of the therapeutic targets for topical application of 1alpha,25-dihydroxyvitamin D3: The possible involvement of transforming growth factor-beta induction. British Journal of Dermatology, 143, pp. 1140-1148.
24. Park, HJ, Kim, HJ, Lee, JH, Lee, JY, Cho, BK, Kang, JS, Kang, H., Yang, Y. and Cho, DH. (2005) Corticotropin releasing hormone (CRH) downregulates interleukin-18 expression in human HaCaT keratinocytes by activation of p38 mitogen-activated protein kinase (MAPK) pathway. Journal of Investigative Dermatology, 124, pp. 751-755.
25. Simonetti, O., Lucarini, G., Goteri, G., Zizzi, A., Biagini, G., Lo Muzio, L and Offidani, A. (2006) VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: Results of an immunohistochemical study. International Journal of Immunopathology & Pharmacology, 19, pp. 751-760.
26. Singer, AJ and Clark, RAF. (1999) Cutaneous wound healing. New England Journal of Medicine, 341, pp. 738-746.
27. Wang, XJ, Greenhalgh, DA, Bickenbach, JR, Jiang, A., Bundman, DS, Krieg, T., Derynck, R. and Roop, DR. (1997) Expression of a dominant-negative type II transforming growth factor beta (TGFbeta) receptor in the epidermis of transgenic mice blocks TGFbeta mediated growth inhibition. Proceedings of the National Academy of Sciences U S A, 94, pp. 2386-2391.
28. Wataya-Kaneda, M., Hashimoto, K., Kato, M., Miyazono, K. and Yoshikawa, K. (1996) Differential localization of TGF-(beta precursor isotypes in psoriatic human skin. Journal of Dermatological Science, 11, pp. 183-188.
29. Wittmann, M., Purwar, R., Hartmann, C., Gutzmer, R. and Werfel, T. (2005) Human keratinocytes respond to interleukin-18: Implication for the course of chronic inflammatory skin diseases. Journal of Investigative Dermatology, 124, pp. 1225-1233.